August 26, 2024Gut

CD64⁺fibroblast-targeted vilanterol and a STING agonist augment CLDN18.2 BiTEs efficacy against pancreatic cancer by reducing desmoplasia and enriching stem-like CD8⁺T cells

View Full Paper

Ask AI

Bookmark

Abstract

The objective of this study is to improve the efficacy of CLDN18.2/CD3 bispecific T-cell engagers (BiTEs) as a promising immunotherapy against pancreatic ductal adenocarcinoma (PDAC).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zhou et al. (2024) studied this question.

synapsesocial.com/papers/68e5adc8b6db643587547490 https://doi.org/10.1136/gutjnl-2024-332371

View Full Paper

Ask AI

Bookmark

Abstract

The objective of this study is to improve the efficacy of CLDN18.2/CD3 bispecific T-cell engagers (BiTEs) as a promising immunotherapy against pancreatic ductal adenocarcinoma (PDAC).